Virgil E.J.C. Schijns

Author

Also Known As

V E J C Schijns, V SCHIJNS, V. E. J. C. Schijns, V. E. SCHIJNS, V. E. Schijns, V. E.J.C. Schijns, V. Schijns, V.E.J.C. Schijns, VIRGIL E.J.C. SCHIJNS, Virgil E J C Schijns

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Wageningen University & Research ET International (United States)University of Southern California University of California, Irvine TuBerculosis Vaccine Initiative

About

Virgil E.J.C. Schijns is an author at Wageningen University & Research specializing in immunology, medicine, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	16	656
2	Immunology	14	16	656
3	Allergy	2	2	100
4	Cell Biology	1	1	32
5	Epidemiology	1	1	13

Virgil E.J.C. Schijns

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Th1/Th2 polarization by viral and helminth infection in birds Winfried G.J. Degen, Nancy van Daal, Lisa Rothwell, Veterinary Microbiology Poultry DiseasePathogenesisImmunologyVirologyVirus-host Interaction	2005	188
Characterization of the First Nonmammalian T2 Cytokine Gene Cluster: The Cluster Contains Functional Single-Copy Genes for IL-3, IL-4, IL-13, and GM-CSF, a Gene for IL-5 That Appears to Be a Pseudogene, and a Gene Encoding Another Cytokinelike Transcript, KK34 Stuart Avery, Lisa Rothwell, Winfried D.J. Degen, Journal of Interferon & Cytokine Research	2004	162
Induction and Direction of Immune Responses by Vaccine Adjuvants Virgil E.J.C. Schijns Critical Reviews in Immunology	2001	97
Identification and Molecular Cloning of Functional Chicken IL-12 Winfried G.J. Degen, Nancy van Daal, Hanneke I. van Zuilekom, The Journal of Immunology	2004	84
Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: Effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model Niels Hagenaars, Enrico Mastrobattista, Harrie L. Glansbeek, Vaccine VaccinationCross-protectionVaccine DevelopmentImmunologyImmunization Route	2008	76
Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4<sup>+</sup>T-lymphocyte counts Daniela A. Bota, Jinah Chung, Manisha Dandekar, CNS Oncology	2018	69
Structure- and oil type-based efficacy of emulsion adjuvants Theo Jansen, Marij P.M. Hofmans, Marc J.G. Theelen, Vaccine PharmacologyEmulsion AdjuvantsEmulsion	2006	55
First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity Virgil E.J.C. Schijns, Chrystel Pretto, Laurent Devillers, Vaccine	2015	55
Structure–activity relations of water-in-oil vaccine formulations and induced antigen-specific antibody responses Theo Jansen, Marij P.M. Hofmans, Marc J.G. Theelen, Vaccine VaccinationAllergyMedicineImmunoengineeringImmunology	2004	52
Potentiation of humoral immune responses to vaccine antigens by recombinant chicken IL-18 (rChIL-18) Winfried G.J. Degen, H VANZUILEKOM, N.C. Scholtes, Vaccine VaccinationHumoral Immune ResponsesMucosal VaccinationAllergyAutoimmune Disease	2005	48

Page 1